Clinical Trial Detail

NCT ID NCT02365766
Title Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Christopher Hoimes, M.D.
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Cisplatin

Pembrolizumab

Gemcitabine

Age Groups: adult

No variant requirements are available.